Literature DB >> 24343109

[Clinical prognosis of schizophrenic patients with cannabis addiction. Between nihilism and hope].

T Schnell1.   

Abstract

Comorbid substance use disorders in schizophrenia are mostly associated with an unfavorable course of the disease and with difficulties in clinical management. Therefore, some therapists tend to react to these patients in a resigned manner. However, there is growing evidence for higher cognitive functioning and less severe deficits in brain morphology of these patients compared to patients without cannabis use. A common interpretation refers to relatively low vulnerability for psychosis in some of these patients, who mainly became schizophrenic because of the pro-psychotic properties of cannabis. Low vulnerability is reflected by a higher cognitive functioning; therefore, the pessimistic view of therapists seems unjustified for at least a subgroup of young patients. Provided that patients are treated in adequate therapeutic settings and that they stop using cannabis, a lower vulnerability may be associated with overall better socio-rehabilitative outcome parameters.

Entities:  

Mesh:

Year:  2014        PMID: 24343109     DOI: 10.1007/s00115-013-3926-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  39 in total

1.  Testing hypotheses about the relationship between cannabis use and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall; Michael Lynskey
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

2.  Cannabis, cocaine, and visuomotor integration: evidence for a role of dopamine D1 receptors in binding perception and action.

Authors:  Lorenza S Colzato; Bernhard Hommel
Journal:  Neuropsychologia       Date:  2008-02-01       Impact factor: 3.139

Review 3.  The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature.

Authors:  Valentina Lorenzetti; Nadia Solowij; Alex Fornito; Dan Ian Lubman; Murat Yucel
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

5.  Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation.

Authors:  P D Morrison; J M Stone
Journal:  Hum Psychopharmacol       Date:  2011-02-23       Impact factor: 1.672

6.  Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.

Authors:  Hiroshi Nagai; Nobuaki Egashira; Kazunori Sano; Ayumi Ogata; Ai Mizuki; Kenichi Mishima; Katsunori Iwasaki; Yukihiro Shoyama; Ryoji Nishimura; Michihiro Fujiwara
Journal:  Pharmacol Biochem Behav       Date:  2006-07-03       Impact factor: 3.533

Review 7.  Cannabis use and earlier onset of psychosis: a systematic meta-analysis.

Authors:  Matthew Large; Swapnil Sharma; Michael T Compton; Tim Slade; Olav Nielssen
Journal:  Arch Gen Psychiatry       Date:  2011-02-07

Review 8.  Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders.

Authors:  N Dekker; D H Linszen; L De Haan
Journal:  Psychopathology       Date:  2009-09-15       Impact factor: 1.944

9.  Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls.

Authors:  Johannes Rentzsch; Almut Penzhorn; Kim Kernbichler; Doris Plöckl; Ana Gómez-Carrillo de Castro; Jürgen Gallinat; Maria C Jockers-Scherübl
Journal:  Exp Neurol       Date:  2007-02-21       Impact factor: 5.330

Review 10.  Effects of cannabis use on outcomes of psychotic disorders: systematic review.

Authors:  Stanley Zammit; Theresa H M Moore; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Br J Psychiatry       Date:  2008-11       Impact factor: 9.319

View more
  1 in total

1.  Trans-Sector Integrated Treatment in Psychosis and Addiction.

Authors:  Euphrosyne Gouzoulis-Mayfrank; Susanne König; Stefan Koebke; Thomas Schnell; Mario Schmitz-Buhl; Jörg Daumann
Journal:  Dtsch Arztebl Int       Date:  2015-10-09       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.